ArticleBMC chemistry2025
Ultra-performance liquid chromatography method for quantitative analysis of nystatin and triamcinolone acetonide in topical creams after in vitro release using franz diffusion cell.
Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microstructural Characterization and In Vitro-In Vivo Evaluation of Drug Release and Permeation in Goupi Plaster.Pharmaceutics · 2026Article
- Development and Evaluation of a Baicalin-loaded Phytosomal Transdermal Patch for Type 2 Diabetes Mellitus.Current drug metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The accurate quantification of active ingredients in topical creams is critical for ensuring efficacy, safety, and quality. Therefore, this initiative is to develop and validate a robust ultra-performance liquid chromatography (UPLC) method for the quantification of nystatin (Nys) and triamcinolone acetonide (TA) in topical creams. Validation of the in vitro release test (IVRT) apparatus and UPLC method was conducted according to standard requirements. IVRT apparatus demonstrated exceptional control over key parameters, aligning with stringent standards, thus ensuring consistent and reproducible drug release profiles. Membrane inertness evaluation confirmed no significant binding of Nys and TA. The proposed UPLC method was found to be linear in the range of 0.65-31.93 µg/mL for TA and 17.67-863.27 IU/mL for Nys with determination coefficients of 1.0000 for both drugs, enabling accurate measurement across a wide range of drug concentrations. Recovery rates and mass balance results were within acceptable ranges, validating the method's accuracy. The IVRT method exhibited low day-1 and day-2 variability, underscoring its reliability. Sensitivity and specificity were comparable to similar studies, demonstrating the method's applicability in distinguishing between different formulation strengths and variations. The method's robustness was confirmed by its resistance to variations in dose amount, receptor media composition, stirring speed (stirring speed is controlled by rotation speed controller connected to the vertical diffusion cell Instrument. Material of construction is plastic, plastic bead is connected to the helix spring and placed in the cell for uniform mixing.), and temperature. The UPLC method validation affirmed its high sensitivity and reliability for detecting low levels of active ingredients, with excellent selectivity, specificity, linearity, precision, accuracy, stability, and robustness. The IVRT equipment's and UPLC analytical method's thorough certification and validation procedures verify its fit for the precise and dependable measurement of Nys and TA in topical cream compositions. These confirmed techniques satisfy all scientific and legal criteria. CLINICAL TRIAL NUMBER: Not Applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.